摘要
目的:检测中重度寻常型银屑病患者阿维A治疗前后血清MCP-4水平的变化。方法:26例中重度寻常型银屑病患者口服阿维A治疗8周。采用ELISA法检测正常对照和银屑病患者治疗前后血清MCP-4的表达水平。结果:寻常型银屑病外周血MCP-4为196.64±35.21 pg/mL,明显高于正常对照组(42.83±9.68 pg/mL),阿维A治疗后血清MCP-4为107.23±21.57 pg/mL,与治疗前相比明显降低(P<0.01),但仍高于正常对照组(P<0.01)。结论:阿维A可能通过调节外周血MCP-4表达水平发挥治疗银屑病作用。
Objective:To investigate the effect of acitretin on serum levels of MCP-4 in the patients with moderate to severe psoriasis vulgaris ( PV) . Methods:Twenty patients with moderate to severe PV were trea-ted with acitretin for 8 weeks. Enzyme-linked immunosorbent assay ( ELISA) was used to detect the serum levels of MCP-4 in healthy controls and patients with PV before and after treatment with acitretin. Results:Serum level of MCP-4 in PV patients was 196.64±35.21pg/mL before the treatment with acitretin, which was significantly higher than that in healthy controls (42.83±9.68 pg/mL). After treatment with acitretin,the ser-um level of MCP-4 was 107.23±21.57 pg/mL which was significantly lower than that before the treatment with acitretin ( P〈0.01) , but still higher than that in healthy controls ( P〈0.01) . Conclusion:Acitretin may affect serum levels of MCP-4, through which plays a role in the treatment of psoriasis vulgaris.
出处
《中国麻风皮肤病杂志》
2014年第9期553-555,共3页
China Journal of Leprosy and Skin Diseases